Work

Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019–2023)

Year: 2025

Type: article

Abstract: ABSTRACT We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of Stenotrophomonas maltophilia consecutively collected from United States medical centers in 2019–2023. Aztreonam-avibactam (MIC 50/90 , 2/4 µg/mL; 99.6% inhibited at ≤8 µg/mL) was the most active compound, followed by trimethoprim-sulfamethoxazole (MIC 50/90 , ≤0.12/0.5 µg/mL; 96.9% susceptible), minocycline (MIC 50/90 , 0.5/2 µg/mL; 89.2% susceptible), and levofloxacin (MIC 50/90 , 1/8 µg/mL; 78.9% susceptible). Aztreonam-avibactam retained potent activity against isolates not susceptible to trimethoprim-sulfamethoxazole, minocycline, and/or levofloxacin (99.3%–100.0% inhibited at ≤8 µg/mL).

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.00124-25

Authors: Helio S. Sader, Mariana Castanheira, S. J. Ryan Arends, Timothy B. Doyle

Institution: JMI Laboratories

Language: English

Topic: Infections and bacterial resistance

Subfield: Endocrinology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4408242200

FWCI: 10.43

Cites: 10

Cited by: 19

Related to: 10